drugset / Trial / NCT01716221

An Objective Double-blind Evaluation of Bupropion and Citalopram in an Individual With Friedreich Ataxia

NCT01716221

Phase 4 Completed 1 enrolled University of Colorado, Denver
RandomizedCrossoverTriple-blindSupportive care

Summary

The purpose of this study is to document the clinical effects of bupropion and citalopram in a single subject with Friedreich Ataxia.

Timeline

Start
2012-10
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 50 mg Oral
Subject Bupropion Small molecule 100 mg Oral
Subject Citalopram Small molecule 10 mg Oral
Subject Citalopram Small molecule 20 mg Oral

Indications